Clinical Advances in

NHL: From Emerging Treatment Strategies to Routine Practice

The programs on this page raise awareness of emergent therapies for NHL, the biological and clinical rationale for these treatments and the supporting evidence, and provide practical guidance on their optimal application in real-world practice.

CME Activities

See All

Polling Question

Related Resources

Downloadable Slide Kit

CAR T-Cell Therapy in NHL

Download

Clinical Reference

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy

Synergistic effect of chimeric antigen receptors and cytokine-induced killer cells: an innovative combination for cancer therapy. Biomedical Research and Therapy

See All

Steering Committee

Gilles Salles, MD, PhD

Steering Committee Chair

Professor of Medicine
Chief of the Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York, United States

Jeremy S. Abramson, MD

Associate Professor of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts, United States

Koji Izutsu, MD, PhD

Chief, Department of Hematology
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan

Marie José Kersten, MD, PhD

Department of Hematology location AMC LYMMCARE (Lymphoma and Myeloma Center Amsterdam)
Amsterdam, Netherlands

Marion Subklewe, MD

Professor for Cellular Immunotherapy
Associate Professor for Hematology
University Hospital of Munich
Munich, Bavaria, Germany

Umberto Vitolo, MD

Hematology Consultant Candiolo Cancer Institute,Fondazione Piemontese per l'Oncologia-IRCCS
Candiolo (Torino), Italy

Steering Committee

Gilles Salles, MD, PhD

Steering Committee Chair

Disclosure: Gilles Salles, MD, PhD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AbbVie; Amgen; Autolus; Celgene; Genmab; Gilead; Janssen; Karyopharm; Kite; Merck; Morphosys; Novartis; Roche; Servier; Takeda

Jeremy S. Abramson, MD

Disclosure: Jeremy S. Abramson, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AbbVie; Allogene; Celgene; EMD Serono; Karyopharm; Kite; Morphosys; Novartis; Roche

Received grants for clinical research from: Celgene; Seattle Genetics

Koji Izutsu, MD, PhD

Disclosure: Koji Izutsu, MD, PhD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AbbVie; Celgene

Served as a speaker or a member of a speakers bureau for: AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai; Dainihon Sumitomo; Eisai; HUYA; Janssen; Kyowa Kirin; Merck Sharpe & Dohme; Mundipharma; Ninon Mediphysics; Novartis; Ono; Takeda

Received grants for clinical research from: AbbVie; AstraZeneca; Bayer; Celgene; Cugai; Daiichi; Incyte; Kyowa Kirin; Pfizer; Sankyo; Solasia; Takeda; Yakult

Marie José Kersten, MD, PhD

Disclosure: Marie Josie Kernsten, MD, PhD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Amgen; Bristol-Myers Squibb; Celgene; Cilag; Gilead; Janssen; Kite; Merck Sharpe & Dohme; Miltenyi Biotech; Novartis; Roche

Served as a speaker or a member of a speakers bureau for: Celgene; Gilead; Kite; Novartis; Roche

Received grants for clinical research from: Celgene; Roche; Takeda

Marion Subklewe, MD

Disclosure: Marion Subklewe, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Amgen; Celgene; Gilead; Novartis; Roche; Seattle Genetics

Served as a speaker or a member of a speakers bureau for: Amgen; Celgene; Gilead

Received grants for clinical research from: Amgen; Gilead; Morphosys; Roche

Umberto Vitolo, MD

Disclosure: Umberto Vitolo, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Celgene; Gilead; Janssen

Served as a speaker or a member of a speakers bureau for: AbbVite; Celgene; Gilead; Novartis; Roche